
Actinium Pharmaceuticals (ATNM) Stock Forecast & Price Target
Actinium Pharmaceuticals (ATNM) Analyst Ratings
Bulls say
Actinium Pharmaceuticals Inc. holds a positive outlook due to promising developments in its drug candidate Actimab-A, which shows potential to enhance the efficacy of established checkpoint inhibitors by selectively depleting myeloid-derived suppressor cells (MDSCs) in solid tumors. The engagement in a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute has positioned Actinium to pursue innovative clinical trials while benefiting from substantial cost savings. The anticipation of initial proof-of-concept data in the second half of 2025 further underscores the company’s strategic advancement and bolsters investor confidence in its future performance.
Bears say
Actinium Pharmaceuticals Inc faces significant risks that could negatively impact its stock performance, primarily due to the possibility of failed or inconclusive clinical trials for its product candidates, Iomab-B and Actimab-A. Additionally, the company's ability to secure adequate funding is a critical factor that could hinder the progression of its drug development pipeline. Despite a notable unmet medical need for effective therapies in acute myeloid leukemia, the lack of financial stability and the uncertainty surrounding clinical outcomes present substantial challenges for the company's future growth prospects.
This aggregate rating is based on analysts' research of Actinium Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Actinium Pharmaceuticals (ATNM) Analyst Forecast & Price Prediction
Start investing in Actinium Pharmaceuticals (ATNM)
Order type
Buy in
Order amount
Est. shares
0 shares